Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Effect of LY450139 on the Long Term Progression of Alzheimer's Disease

NCT00594568 ·Status: COMPLETED ·Phase: PHASE3

A Safety Study of LY2886721 Single Doses in Healthy Subjects

NCT01133405 ·Status: COMPLETED ·Phase: PHASE1

Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

NCT00329082 ·Status: COMPLETED ·Phase: PHASE2

A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.

NCT00765115 ·Status: COMPLETED ·Phase: PHASE1

Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo

NCT00762411 ·Status: COMPLETED ·Phase: PHASE3

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

NCT05463731 ·Status: COMPLETED ·Phase: PHASE3

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

NCT06657768 ·Status: RECRUITING ·Phase: PHASE1

Treatment for Aggression and Agitation in Patients With Alzheimer's Disease

NCT00843518 ·Status: COMPLETED ·Phase: PHASE2

A Safety Study of LY2811376 Single Doses in Healthy Subjects

NCT00838084 ·Status: COMPLETED ·Phase: PHASE1

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

NCT01561430 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Safety Study of LY2886721 Multiple Doses in Healthy Subjects

NCT01227252 ·Status: COMPLETED ·Phase: PHASE1

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

NCT03518073 ·Status: COMPLETED ·Phase: PHASE2

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

NCT00930059 ·Status: COMPLETED ·Phase: PHASE2

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

NCT06297590 ·Status: RECRUITING ·Phase: PHASE1

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

NCT02624778 ·Status: COMPLETED ·Phase: PHASE1

Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease

NCT00911807 ·Status: COMPLETED ·Phase: PHASE2

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

NCT04640077 ·Status: COMPLETED ·Phase: PHASE2

A Study of LY3002813 in Participants With Alzheimer's Disease

NCT01837641 ·Status: COMPLETED ·Phase: PHASE1

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

NCT01690195 ·Status: TERMINATED ·Phase: PHASE2

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

NCT03367403 ·Status: COMPLETED ·Phase: PHASE2

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

NCT01723826 ·Status: COMPLETED ·Phase: PHASE2

A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia

NCT02791191 ·Status: TERMINATED ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

NCT01343966 ·Status: COMPLETED ·Phase: PHASE2

A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

NCT03019536 ·Status: COMPLETED ·Phase: PHASE1